TRENDS

• Top 10 PHARMA JAPAN Articles of 2024
  December 25, 2024

• Top 10 Most-Read PHARMA JAPAN Articles in 2023
  December 28, 2023

• Top 10 PHARMA JAPAN Articles in 2022
  December 28, 2022

• 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
  December 28, 2021

• Top 10 PHARMA JAPAN Articles in 2021
  December 28, 2021

• Top 10 PHARMA JAPAN Articles in 2020
  December 28, 2020

• 51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases
  December 27, 2019

• Top 10 PHARMA JAPAN Articles in 2019
  December 26, 2019

• Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up
  August 30, 2019

• Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
  August 9, 2019

• Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
  July 16, 2019

• Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
  July 4, 2019

• Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
  July 3, 2019

• 12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
  June 21, 2019

• Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too
  June 18, 2019

• Female Manager Ratios at Foreign Drug Makers Rising in Japan, 7 Out of 10 Log 20%-Plus
  May 28, 2019

• Cancer Drugs Underpin Big Pharmas’ Japan Revenue in 2018
  April 25, 2019

• Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter
  March 5, 2019

• Industry Workforce Dwindling as More and More Staffers Take Voluntary Retirement; Astellas Could Cut 700 Jobs
  February 22, 2019

• Rituxan Biosimilar Grabs 30% Volume Share in Just 1 Year; Sales Expected to Double in 2019
  February 12, 2019

ページ